Entropy Technologies LP Sells 593 Shares of Unum Group (NYSE:UNM)

Entropy Technologies LP reduced its position in Unum Group (NYSE:UNM) by 10.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,132 shares of the financial services provider’s stock after selling 593 shares during the quarter. Entropy Technologies LP’s holdings in Unum Group were worth $375,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Charles Schwab Investment Management Inc. lifted its position in Unum Group by 1.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 5,500,508 shares of the financial services provider’s stock valued at $326,950,000 after purchasing an additional 55,014 shares during the last quarter. Franklin Resources Inc. lifted its position in Unum Group by 50.0% during the third quarter. Franklin Resources Inc. now owns 469,342 shares of the financial services provider’s stock valued at $29,554,000 after purchasing an additional 156,380 shares during the last quarter. Blue Trust Inc. lifted its holdings in shares of Unum Group by 44.1% in the 4th quarter. Blue Trust Inc. now owns 16,495 shares of the financial services provider’s stock worth $1,205,000 after acquiring an additional 5,047 shares during the last quarter. Thrivent Financial for Lutherans lifted its holdings in shares of Unum Group by 89.5% in the 3rd quarter. Thrivent Financial for Lutherans now owns 111,831 shares of the financial services provider’s stock worth $6,647,000 after acquiring an additional 52,813 shares during the last quarter. Finally, Kovitz Investment Group Partners LLC bought a new stake in shares of Unum Group in the 3rd quarter worth approximately $1,074,000. 86.57% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently commented on UNM shares. Jefferies Financial Group lifted their target price on shares of Unum Group from $91.00 to $96.00 and gave the stock a “buy” rating in a research note on Tuesday, December 10th. Morgan Stanley boosted their price objective on shares of Unum Group from $62.00 to $64.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 30th. Wells Fargo & Company boosted their price objective on shares of Unum Group from $74.00 to $81.00 and gave the company an “overweight” rating in a research report on Tuesday, January 14th. Truist Financial boosted their price objective on shares of Unum Group from $70.00 to $75.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Finally, Barclays upped their target price on shares of Unum Group from $76.00 to $85.00 and gave the stock an “overweight” rating in a research report on Monday, January 6th. Five analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $80.33.

Insider Activity

In other Unum Group news, EVP Timothy Gerald Arnold sold 10,000 shares of the stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $76.92, for a total transaction of $769,200.00. Following the completion of the sale, the executive vice president now directly owns 54,827 shares of the company’s stock, valued at $4,217,292.84. This trade represents a 15.43 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Richard P. Mckenney sold 58,865 shares of the stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $75.39, for a total value of $4,437,832.35. Following the transaction, the chief executive officer now owns 1,007,003 shares of the company’s stock, valued at $75,917,956.17. This represents a 5.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 83,865 shares of company stock valued at $6,315,082 in the last quarter. 0.93% of the stock is currently owned by insiders.

Unum Group Stock Performance

Shares of Unum Group stock opened at $75.18 on Thursday. The company has a debt-to-equity ratio of 0.32, a current ratio of 0.29 and a quick ratio of 0.28. The stock has a market cap of $13.73 billion, a price-to-earnings ratio of 7.94, a PEG ratio of 1.17 and a beta of 0.80. The firm’s 50-day moving average is $74.21 and its 200 day moving average is $65.87. Unum Group has a 1 year low of $47.65 and a 1 year high of $79.43.

Unum Group (NYSE:UNM) last posted its earnings results on Tuesday, February 4th. The financial services provider reported $2.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.14 by ($0.11). Unum Group had a net margin of 13.81% and a return on equity of 14.91%. Sell-side analysts anticipate that Unum Group will post 9.12 EPS for the current fiscal year.

Unum Group Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Friday, January 24th will be paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 2.23%. The ex-dividend date of this dividend is Friday, January 24th. Unum Group’s dividend payout ratio is currently 17.74%.

Unum Group Company Profile

Unum Group, together with its subsidiaries, provides financial protection benefit solutions primarily in the United States, the United Kingdom, Poland, and internationally. It operates through Unum US, Unum International, Colonial Life, and Closed Block segment. The company offers group long-term and short-term disability, group life, and accidental death and dismemberment products; supplemental and voluntary products, such as individual disability, voluntary benefits, and dental and vision products; and accident, sickness, disability, life, and cancer and critical illness products.